BIIB logo
BIIB NASDAQ US

Biogen Inc. - Common Stock

Healthcare · Biotechnology Website · IPO Sep 1991
$177.34
▼ $-6.44 (-3.50%)
Vol 1.3M
11
Quality Score
ok
Deep Check
1/5 fail
Mkt Cap
$25.8B
P/E
16.0
ROE
9.3%
Margin
16.0%
D/E
34.52
Beta
0.14
52W
$110–$185

Wall Street Consensus

43 analysts · Apr 2026
9
Strong Buy
11
Buy
22
Hold
1
Sell
0
Strong Sell
46.5%
Buy Rating

Price Chart

About Biogen Inc. - Common Stock

Biogen (BIIB) — це велика біотехнологічна компанія, що спеціалізується на неврологічних та нейродегенеративних захворюваннях. Вона є лідером у розробці ліків для розсіяного склерозу та хвороби Альцгеймера, хоча стикається з конкуренцією з боку інших великих фармацевтичних компаній та біотехнологічних стартапів. Ключова перевага Biogen — це її багаторічний досвід та портфель затверджених препаратів у цих складних терапевтичних областях.

Earnings

Beat rate: 100.0%
Quarter EPS Est EPS Act Surprise
Dec 2025 $1.65 $1.99 +$0.34
Sep 2025 $3.96 $4.81 +$0.85
Jun 2025 $3.94 $5.47 +$1.53
Mar 2025 $2.58 $3.02 +$0.44

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) 9.0% 9.0% 9.0% 9.0% 9.2% 9.2%
P/E (TTM) 12.02 13.27 14.44 14.78 16.32 16.05
Net Margin 24.0% 15.3% 15.3% 15.3% 16.0% 16.0%
Gross Margin 77.1% 75.4% 75.4% 75.4% 75.2% 75.2%
D/E Ratio 35.63 35.63 35.63 35.63 34.52 34.52
Current Ratio 2.50 2.50 2.50 2.50 2.72 2.72

Key Ratios

ROA (TTM)
5.7%
P/S (TTM)
2.56
P/B
1.3
EPS (TTM)
$10.97
CF/Share
$13.34
Rev Growth 3Y
-4.1%
52W High
$185.17
52W Low
$110.04
$110.04 52-Week Range $185.17

How does BIIB compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

BIIB AAPG ABEO ABOS ABP

BIIB valuation vs Biotechnology peers

P/E ratio
16.1
15% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.6
80% below peers (12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.3
46% below peers (2.5)
vs Peers
vs Industry
Undervalued
Div yield
0% below peers (0.0%)
vs Peers
vs Industry
Low yield

BIIB profitability vs Biotechnology peers

ROE
9.3%
114% above peers (-67.3%)
vs Peers
vs Industry
Top tier
Net margin
16.0%
106% above peers (-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
75.2%
4% below peers (78.6%)
vs Peers
vs Industry
Weak
ROA
5.7%
112% above peers (-46.7%)
vs Peers
vs Industry
Top tier

BIIB financial health vs Biotechnology peers

D/E ratio
34.5
0% below peers (0.0)
vs Peers
vs Industry
High debt
Current ratio
2.7
39% below peers (4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.1
85% below peers (1.0)
vs Peers
vs Industry
More volatile

BIIB fundamentals radar

BIIB Peer median Industry

BIIB profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

BIIB vs peers: key metrics

Latest AI Opinion

Grok SKIP

Price action shows a strong uptrend from ~$110 lows in April 2025 to a peak near $201 in early February 2026, but the stock has pulled back ~9% to the current $182.59 level over the past month with lower volume, …

Mar 24, 2026